The company has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. Recent strategic backing from Sanofi ($20 million) alongside €60 million total financing demonstrates confidence in the pipeline focused on genetic medicine.
Cyborg Score Rationale
Early-stage biotech with advanced gene therapy programs and recent major pharma validation (Sanofi investment), but pre-revenue status and limited commercial data create significant execution risk. Recent leadership transition adds uncertainty.
Top Insights
Sanofi strategic investment (Jan 2026) signals confidence in gene therapy approach and de-risks capital requirements
Dual-pronged strategy: near-term small molecule (SENS-401) in Phase 2 for acquired hearing loss plus gene therapies for monogenic deafness
Institut Pasteur collaboration provides genetic expertise and credibility for monogenic hearing loss programs
Pre-revenue model with €6.65M revenue (2024) suggests grant/licensing income; profitability timeline tied to Phase 2 clinical outcomes
Named Competitors
Hearing Loss Gene Therapy Platform — Large pharma exploring gene therapy for hereditary hearing loss
Cochlear Implants — Medical device partner on SENS-401 Cochlear study
Recent Developments
(January 2026) €60 million financing secured with €20M strategic investment from Sanofi
(January 2026) CEO Nawal Ouzren steps down; Amit Munshi assumes leadership
(February 2026) Company participation in Association for Research in Otolaryngology 49th Annual Meeting
Open the full interactive Sensorion report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.